# Trigeminal Neuralgia: Medical and Surgical Management

## Introduction

Trigeminal neuralgia is a severe, episodic facial pain syndrome characterized by sudden, unilateral, brief, stabbing, recurrent pain in the distribution of one or more branches of the trigeminal nerve. It is among the most painful conditions known, with an incidence of approximately 4 to 13 per 100,000 per year and a female predominance.

## Classification

### International Classification

Classical trigeminal neuralgia is caused by neurovascular compression at the root entry zone, most commonly by the superior cerebellar artery. Secondary trigeminal neuralgia is caused by an identifiable neurological disease such as multiple sclerosis or a cerebellopontine angle tumor. Idiopathic trigeminal neuralgia has no identifiable cause on imaging or at surgery.

### Clinical Subtypes

Type 1 features predominantly paroxysmal, sharp, shooting pain with pain-free intervals between attacks. Type 2 presents with constant aching or burning pain with superimposed paroxysms. This distinction is clinically important because Type 1 responds better to surgical intervention than Type 2.

## Clinical Presentation

Pain distribution most commonly involves V2 (maxillary) and V3 (mandibular) divisions; V1 (ophthalmic) alone is rare. Trigger zones are activated by light touch to the face, chewing, brushing teeth, wind, or talking. A characteristic refractory period follows each paroxysm, during which triggers do not provoke attacks. The neurological examination is typically normal in classical trigeminal neuralgia; the presence of neurological deficits should prompt investigation for secondary causes.

## Diagnostic Workup

MRI of the brain with a dedicated trigeminal protocol using thin-cut CISS or FIESTA sequences visualizes neurovascular contact at the root entry zone. MRA identifies the offending vessel, most commonly the superior cerebellar artery, AICA, or vertebrobasilar dolichoectasia. Secondary causes must be excluded, including demyelinating plaques in the pons from multiple sclerosis and cerebellopontine angle tumors such as meningioma, vestibular schwannoma, or epidermoid. Trigeminal reflex testing and neurophysiology can provide supportive diagnostic information.

## Medical Management

### First-Line Therapy

Carbamazepine at 200 to 1200 milligrams per day is the first-line treatment with a number needed to treat of 1.7 to 1.8, supported by Class I evidence. Oxcarbazepine at 600 to 1800 milligrams per day offers similar efficacy with fewer drug interactions and is an acceptable first-line alternative.

### Second-Line and Adjunctive Agents

Baclofen at 30 to 80 milligrams per day, lamotrigine at 200 to 400 milligrams per day, and gabapentin or pregabalin as adjunctive agents are options for incomplete response. Botulinum toxin A via subcutaneous injection has shown benefit in refractory cases.

## Surgical Management

### Microvascular Decompression

MVD is the gold standard surgical treatment for classical trigeminal neuralgia with confirmed neurovascular compression. The procedure uses a retrosigmoid craniotomy approach to the cerebellopontine angle. The offending vessel is identified and mobilized, and Teflon felt is interposed between the vessel and the nerve to prevent recurrent compression. Outcomes include 80 to 90 percent initial pain relief with 70 to 75 percent remaining pain-free at 10 years. Risks include hearing loss in 1 to 2 percent, CSF leak in 2 percent, facial numbness in 3 to 5 percent, cerebellar injury, and mortality below 0.5 percent.

### Percutaneous Procedures

Three percutaneous approaches access the trigeminal ganglion through the foramen ovale under fluoroscopic guidance via the Hartel approach. Percutaneous balloon compression provides mechanical compression of the Gasserian ganglion. Radiofrequency thermocoagulation achieves selective thermal lesioning of trigeminal rootlets. Glycerol rhizolysis creates chemical injury to trigeminal rootlets within Meckel's cave. Initial relief rates are 70 to 90 percent, but recurrence rates are higher than MVD at approximately 50 percent at 3 to 5 years. These procedures are preferred in elderly patients or those with significant medical comorbidities who cannot tolerate posterior fossa surgery.

### Stereotactic Radiosurgery

Gamma Knife radiosurgery delivers focused radiation of 70 to 90 Gy to the trigeminal root entry zone. Pain relief is delayed by weeks to months after treatment. Initial relief occurs in 70 to 80 percent, with recurrence in 30 to 50 percent at five years. It carries the lowest procedural risk profile of all surgical options and is ideal for high-surgical-risk patients.

## Treatment Algorithm

Management begins with carbamazepine or oxcarbazepine as first-line medical therapy. Combination therapy or alternative medications are tried for partial response. Surgical referral is appropriate for medically refractory cases or intolerable medication side effects. MVD is preferred for younger, medically fit patients with demonstrated neurovascular compression on MRI. Percutaneous procedures or radiosurgery are chosen for elderly or medically frail patients, or for recurrence after MVD.

| Procedure | Initial Pain Relief | Long-Term Pain-Free (10 yr) | Recurrence | Best Candidate |
|-----------|-------------------|---------------------------|------------|----------------|
| MVD | 80-90% | 70-75% | Lowest | Young, fit, confirmed NVC |
| Percutaneous (balloon/RF/glycerol) | 70-90% | ~50% at 3-5 yr | Moderate-High | Elderly, comorbid, no posterior fossa access |
| Gamma Knife SRS | 70-80% | 50-70% at 5 yr | 30-50% | High surgical risk, recurrence after MVD |

## Clinical Pearls

A normal neurological examination is expected in classical trigeminal neuralgia; any trigeminal sensory loss or other cranial nerve deficit mandates further investigation for secondary causes including tumors and multiple sclerosis. The carbamazepine response is so characteristic of trigeminal neuralgia that failure to respond should prompt reconsideration of the diagnosis. MVD offers the highest rate of long-term pain freedom and is the only procedure that addresses the underlying pathophysiology without intentional nerve injury. Venous compression is a less favorable prognostic indicator for MVD outcome compared to arterial compression.

## References
1. Cruccu G, Di Stefano G, Truini A. Trigeminal neuralgia. N Engl J Med. 2020;383(8):754-762.
2. Barker FG II, Jannetta PJ, Bissonette DJ, et al. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med. 1996;334(17):1077-1083.
3. Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia. Neurology. 2008;71(15):1183-1190.
4. Zakrzewska JM, Linskey ME. Trigeminal neuralgia. BMJ. 2014;348:g474.